4yr
Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34406609/
Erenumab is a monoclonal antibody, targeted against the calcitonin gene-related peptide (CGRP) receptor. Clinical studies have demonstrated prophylactic efficacy in both episodic (EM) and chronic migraine (CM). The aim of the present study is to evaluate the efficacy of treatment in tertiary headach ...
• Conclusion: “This study shows the effectiveness of 70 mg erenumab treatment in previously therapy-refractory migraine patients under real-life conditions at two independent headache centers.”
• In this retrospective study, German researchers assessed the efficacy of treatment with erenumab during three months before and after initiation of treatment in 82 migraine patients. The researchers noted a significant decrease in headache days, as well as a decrease in average intensity and duration of headache attacks.
• The monoclonal antibody erenumab targets the calcitonin gene-related peptide (CGRP) receptor, and has been shown to exert prophylactic efficacy in both episodic (EM) and chronic migraine (CM).
• “Our data also provide information regarding the therapeutic effect of erenumab in patients with MOH [medication overuse headache],” wrote the authors. “The 50% responder rate and reduction of monthly headache days are as good as in patients without MOH. This is in line with a previous study. These results suggest that patients with MOH benefit from erenumab even without performing a withdrawal of acute medication.”
• Limitations of the study include certain incomplete data sets. Furthermore, during antibody therapy, the researchers did not assess additional drugs or non-drug treatment. The researchers also limited assessment to headache days and did not include migraine days.